A real-world study of effectiveness and safety of generic and original clopidogrel in the treatment of acute coronary syndrome
- VernacularTitle:仿制和原研氯吡格雷治疗急性冠脉综合征有效性及安全性的真实世界研究
- Author:
Bing LUO
1
,
2
;
Xian YANG
1
;
Yixuan LI
1
,
2
;
Congling CHEN
1
,
2
;
Simin YAN
1
;
Xi LAN
3
;
Xue BAO
3
;
Feng YU
2
;
Weihong GE
1
Author Information
1. Dept. of Pharmacy，Nanjing Drum Tower Hospital，China Pharmaceutical University，Nanjing 210009，China
2. School of Basic Medicine and Clinical Pharmacy，China Pharmaceutical University，Nanjing 210009，China
3. Dept. of Cardiology，Nanjing Drum Tower Hospital，China Pharmaceutical University，Nanjing 210009，China
- Publication Type:Journal Article
- Keywords:
clopidogrel;
acute coronary syndrome;
dual antiplatelet therapy;
domestic generic drug;
imported original drug
- From:
China Pharmacy
2023;34(6):724-729
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the clinical effectiveness and safety of domestic generic and imported original clopidogrel for antiplatelet therapy in patients with acute coronary syndrome （ACS）. METHODS The clinical data of ACS patients in Nanjing Drum Tower Hospital of China Pharmaceutical University from January 2020 to June 2021 were retrospectively collected by using electronic medical record system， and the patients were divided into original drug group （321 cases） and generic drug group （328 cases） according to the drug use. Both groups were given dual antiplatelet therapy with clopidogrel and aspirin. The effectiveness and safety outcomes of the two groups were followed up for 12 months and compared， the related influential factors were analyzed. RESULTS Major adverse cardiovascular events （MACE） occurred in 16 and 22 patients in original drug group and generic drug group respectively， including nonfatal myocardial infarction （4 and 5 cases）， stroke （2 and 4 cases）， revascularization （8 and 3 cases）， cardiovascular related death （2 and 4 cases）， and all-cause death （4 and 6 cases）. There were 12 and 7 patients with major bleeding events， 38 and 29 patients with minor bleeding events， and 33 and 21 patients with non-bleeding adverse events. There was no statistically significant difference in the cumulative incidence of related events （P values of Log-Rank tests were all greater than 0.05）. Cox regression analysis showed that the use of generic clopidogrel did not increase the risk of MACE and major bleeding events in ACS patients [hazard ratio of 1.305 and 0.416， 95% confidence interval of （0.678， 2.512） and （0.155， 1.117）， respectively， P＞0.05]， and the combination of proton pump inhibitors （PPI） could reduce the risk of major bleeding events [hazard ratio of 0.196， 95% confidence interval of （0.063， 0.611）， P＜0.05]. CONCLUSIONS Compared with imported original drug， domestic generic clopidogrel has similar clinical effectiveness and good safety. Combined use of PPI may be a beneficial factor to reduce the occurrence of major bleeding events in patients.
